Allele provides cGMP-aligned iPSC banking services as part of its integrated iPSC platform to support cell therapy development and manufacturing. iPSC banking is performed under controlled conditions and within established quality systems to ensure traceability, consistency, and long-term usability of well-characterized iPSC materials.
Our iPSC banking activities are closely integrated with upstream iPSC line development, single cell cloning, expansion, and refinement workflows. Banking procedures are conducted following defined protocols and documentation practices to maintain identity, stability, and integrity of banked iPSC lines throughout their lifecycle.
iPSC banks are established and maintained to support downstream development, manufacturing readiness, and program continuity. All banking activities are aligned with cGMP principles and are managed within a structured framework that supports controlled handling, documentation, and quality oversight, ensuring compatibility with regulatory expectations.
As part of Allele’s GMP iPSC offering, banking provides a reliable foundation for both off-the-shelf and customized iPSC strategies. Our approach enables seamless integration with quality control, manufacturing, and future program advancement without introducing unnecessary complexity or risk.
If your projects are at the pre-clinical or early clinical phases, Allele Biotech’s cGMP banking service can significantly save your budget and time associated with setting up, operating and maintaining a cGMP banking unit alone. If you are interested in this service, please contact us via email at info@allelebiotech.com.
